Technology Hurdles: Drug Developer Perspective

Similar documents
Her 2 Positive Metastatic Breast Cancer

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015

XII Michelangelo Foundation Seminar

Immunoconjugates in Both the Adjuvant and Metastatic Setting

HER2-Targeted Rx. An Historical Perspective

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

Novel Biomarkers (Kallikreins) for Prognosis and Therapy Response in Ovarian cancer

CANCER. Clinical Validation of Breast Cancer Predictive Markers

XII Michelangelo Foundation Seminar

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario

Corporate Medical Policy

Targe:ng HER2 in Metasta:c Breast Cancer in 2014

A vision for HER2 future

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives

Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

New Drug Development in HER2+ Breast Cancer

Systemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We

INDIVIDUALIZED THERAPY OF METASTATIC BREAST CANCER Lance A. Liotta MD PhD

Herceptin Pivotal Studies

HER2/neu Evaluation of Breast Cancer in 2019

A Fully Integrated Cancer Company.

FDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.

Media Release. FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer

Systemic Therapy of HER2-positive Breast Cancer

PIK3CA Mutations in HER2-Positive Breast Cancer

Advanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD

Her 2 Positive Advanced Breast Cancer: From Evidence to Practice

Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon

HER2-positive Breast Cancer

Non-hormonal therapies in advanced breast cancer: new and emerging approaches

Assessment Run B HER-2

confirmatory clinical trials - The PMDA Perspective -

R&D DAY. June 14, 2016

Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer

ACRIN Gynecologic Committee

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva

Accelerated approval of Perjeta for neoadjuvant use also converted to full approval

Understanding your biomarker: what this marker can do for you

Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

MEDICAL POLICY. Proprietary Information of YourCare Health Plan

Precision Medicine Lessons from meta-analyses of 70,253 patients

Priti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract

Design considerations for Phase II trials incorporating biomarkers

Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer

patients in the era of

Possible causes of difference among regions How to look at the results from MRCT Non-compliance with GCP and/or protocol Apparent Differences (Play of

Third Quarter 2015 Earnings Call. November 9, 2015

Reviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:

EGFR inhibitors in NSCLC

When is Chemotherapy indicated in Advanced Luminal Breast Cancer?

José Baselga, MD, PhD

AVANCES EN METODOLOGÍA DE LA INVESTIGACIÓN. Alberto Ocaña Hospital Universitario de Albacete

PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients

Controversies in HER2 Oncogene Testing: What Constitutes a True Positive Result in Patients With Breast Cancer?

Overcoming resistance to endocrine or HER2-directed therapy

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot

Accelerating Innovation in Statistical Design

Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento

Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

The issues that will be resolved through PMCs include the the requalification of bioburden test.

Treatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London

Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego

Outline of the presentation

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?

Development of Rational Drug Combinations for Oncology Indications - An Industry Perspective

Media Release. Basel, 3 June 2012

Dr. dr. Primariadewi R, SpPA(K)

Media Release. FDA grants Priority Review for Roche s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer

DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA

The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?

Objectives. Briefly summarize the current state of colorectal cancer

Update on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT

Update in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France

Metastatic Breast Cancer What is new? Subtypes and variation?

Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example

Life Sciences Consortium Task Force Report to The National Cancer Policy Forum Workshop

T he HER2/neu type 1 tyrosine kinase growth factor

Quality & Quantity of life in oncology What the CT doesn t tell us. Baby boomers have gone grey!

Role of Primary Resection for Patients with Oligometastatic Disease

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

Recent advances in the management of metastatic breast cancer in older adults

Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

Predicting outcome in metastatic breast cancer

Three Hours Thirty Minutes

Non-Anthracycline Adjuvant Therapy: When to Use?

Emerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ

IRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca

Estimating and explaining survival time in metastatic breast cancer

A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress

1.5. Research Areas Treatment Selection

Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer

Transcription:

Technology Hurdles: Drug Developer Perspective Robert Mass, MD Senior Director Genentech, Inc. June 8, 2009

Diagnostic challenges Genentech has been committed to personalized drug development in oncology since Herceptin In spite of this commitment, our efforts to improve the lives of individual patients have been challenged by: The differential pace of therapeutic drug development/innovation when compared to diagnostic innovation Example: Herceptin and HER2 testing The technical challenges of pre-clinical to clinical diagnostic transition Example: Pertuzumab and HER2 pathway activation The regulatory environment governing the linkage of diagnostic testing and targeted therapy More about that tomorrow Page 2

The Herceptin program had a viable biomarker from day 1 1.0 Amplification Level : > 10 5-10 2-5 1 1 Disease-free survival probability 0.8 0.6 0.4 0.2 Not amplified (n = 52) Amplified (n = 11) > 5 copies 12.5 kb - 4.4 kb - p185 - Southern Northern Western 0.0 0 12 24 36 48 60 72 84 Time (months) Frozen IHC 27% 63% % Women 10% Slamon et al., Science 235:177-182, 1987 Slamon et al., Science 244: 707-712, 1989

The Herceptin program had a viable biomarker from day 1 HER2 Expression Level SK-BR-3 BT-474 MDA-MB-361 MDA-MB-453 MDA-MB-436 ZR-75-1 MDA-MB-231 MCF7 33 25 16.7 16.7 3.3 3.3 1.2 1.2 Cell line HER2/cell* IHC score FISH Score MDA-231 21,600 0 1.1 MDA-175 92,400 1+ 1.3 MDA-361 ~500.000 2+ ~4 SK-BR BR-3 2,390,000 3+ ~8 * Scatchard analysis 0 20 40 60 80 100 Growth Inhibition (%) Antibody Inhibiton (4D5) of Anchorage-Independent Growth Is Related to HER2 Expression Level HER2 IHC score is directly correlated to HER2 density and amplification

And The Rest is History Probability of Survival 1.0 0.8 0.6 0.4 0.2 0.0 Risk ratio = 0.80 95% Cl = 0.64, 1.00 Herceptin + Chemo (n = 235) Chemo Alone (n = 234) 0 10 20 30 40 50 Months

But not so Fast...FISH is here! Orange: Green: HER-2/ 2/neu Chromosome 17 centromere < 2.0 Not Amplified (FISH-) 2.0 Amplified (FISH+)

FISH score distribution in the pivotal Herceptin study 27.9% of study patients were not HER2 amplified 70 60 Number of Cases 50 40 30 20 10 0 1 2 4 6 8 10 12 14 16 18 FISH Ratios 20

Outcome by FISH score in the pivotal Herceptin study FISH+ FISH - Probability of Survival 1.0 0.8 0.6 0.4 0.2 0.0 Herceptin + Chemo (n = 164) Risk ratio = 0.69 95% Cl = 0.53, 0.91 Chemo Alone (n = 161) 1.0 0.8 0.6 0.4 0.2 0.0 Herceptin + Chemo (n = 62) Risk ratio = 1.07 95% Cl = 0.70, 1.63 Chemo Alone (n = 64) 0 10 20 30 40 50 Months 0 10 20 30 40 50 Months Mass R. et al., Clinical Breast Cancer 6:240-46, 2005

What did this entail? Minimizing loss of informative samples Sufficiently validating novel technology Enabled 96% of patients to be included in outcomes analysis Bridging concordance with our FDA approved diagnostic HercepTest vs PathVysion Replicating results 799 samples were analyzed in 2 independent laboratories Time Project initiated in April 1999, FDA approval April 2002 Page 9

Where we are now (but what about CISH, qrt-pcr, or the next real [or perceived] innovation?) Page 10

Pertuzumab What do you do when you don t have a viable biomarker from the start?

Trastuzumab vs Pertuzumab Both anti-her2 antibodies, but distinct epitopes & MOA s Trastuzumab Herceptin Pertuzumab

The start of a pertuzumab biomarker 293/HERX LXFE 211 LXFA 289 LXFA 297 LXFE 397 LXFA 526 LXFL 529 LXFA 629 LXFA 1041 LXFL 1072 LXFE 211 LXFA 289 LXFA 297 LXFE 397 LXFA 526 LXFL 529 LXFA 629 LXFA 1041 LXFL 1072 HER1 A HER1/2 HER2 B HER 2/3 HER3 rhumab 2C4 responsive rhumab 2C4 responsive Not associated with HER receptors Associated with HER heterodimers Data: B. Bossenmaier & H. Koll

How do we detect HER2 heterodimers in clinical samples? (harder than you think) HER2 activation pher2 Directly detect HER dimers Immunoprecipitation and blotting Heterodimer ELISA Development of heterodimer-specific antibody reagents FRET (fluorescence resonance energy transfer) Proximity assays Surrogate markers for receptor activation Gene expression profile Proteomic profile Downstream regulated gene activity

The nearly impossible clinical experiment 1.0 Proportion progression-free 0.8 0.6 0.4 0.2 Median TTP pher2 positive n=8 20.9 weeks pher2 negative n=20 5.8 weeks pher2 unknown n=27 9.1 weeks All subjects n=55 6.6 weeks All patients treated with pertuzumab 0 0 100 200 300 400 Time to disease progression (days) Every patient underwent laparoscopic biopsy for study entry Gordon et al. J Clin Oncol. 2005;23:16S (abstract 5051). Gordon et al. J Clin Oncol. In press.

Our next trip to the plate Ovarian cancer Platinum-resistant Gemcitabine + Placebo Gemcitabine + Pertuzumab N= 130 1 o EP = PFS Control Pertuzumab 2.6 2.9

The ensuing diagnostic interrogation..

This is an example of detecting HER2 dimerization via downstream regulated gene activity 3.5 3 CTRL HRG Pert + HRG Pert 2.5 6h stimulation Fold CTRL 2 1.5 1 0.5 0 6 out of 8 OvCa cell lines down-regulate HER3 mrna expression after HRG stimulation

Our current trip to the plate in ovarian cancer 1 o EP = PFS Looking for a big treatment effect in a small, selected population

But what about HER2 amplification? HER2+ MBC Progressed on Herceptin Herceptin + Pertuzumab 2 R or 1 R + 12 SD or 13 SD in 1 st 24 patients? YES NO Stage 2 (n=66) Stop trial Complete response a 5 (7.6) Partial response a 11 (16.7) Stable disease for 8 cycles (~6 months) n (%) 17 (25.8) Objective response rate 16 (24.2) Clinical benefit rate b 33 (50.0) Gelmon et al. J Clin Oncol 2008;26(15S): Abstract 1026

But what about HER2 amplification? CLEOPATRA HER2+ MBC (n=800) Docetaxel + trastuzumab + placebo Docetaxel + trastuzumab + pertuzumab An international Phase III randomized, double-blind, placebo-controlled study (approximately 250 sites worldwide) Enrollment stratified by: Prior treatment for breast cancer Geographic region of enrollment Endpoints: PFS and OS Quality of life Biomarker analysis

Conclusions In retrospect, Herceptin was the exception, not the rule This is a lot harder than we thought! A major technologic hurdle remains the availability of appropriately processed tissue for exploratory biomarker assessments FFPE material is a bad platform.most of the time Page 22

Our Touchstone: The Diagnostic Iceberg Page 23